The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European ...

Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s ...

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Johnson & Johnson presented its financial results for the last quarter of 2024, the year as a whole, and its guidance for ...

Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets ...

Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million.

Xilio Therapeutics reports mixed Phase II results for vilastobart with Tecentriq in colorectal cancer. While showing promise in some subsets with a 27% ORR, efficacy in patients with liver metastases ...

Patients For Affordable Drugs, Public Citizen, Social Security Works and other campaigners are to gather in Washington, DC next week with the aim of delivering a message to pharma.

Flagship Pioneering partners with CUHP and MTI to advance research, clinical translation, and talent development in the UK. The collaboration gives Flagship’s companies access to Cambridge’s resources ...

New York-based biotech Tiziana Life Sciences today announces its intention not to engage in a capital raising activities for the immediate future.

And if you’re not thinking data first too - prioritizing your data quality - you risk falling behind your competition and missing out on valuable opportunities.